Marie J. E. Walenkamp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marie J. E. Walenkamp has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
A.S. Richter
1 shared publicationAnita C S Hokken-Koelega
Dutch Growth Research Foundation, Rotterdam, Netherlands
1 shared publicationB.S. Kalzenellenbogen
1 shared publication- Christiaan de Bruin
Division of Endocrinology, Department of Pediatrics, Willem-Alexander Children’s Hospital, Leiden University Medical Center , Leiden 2333 ZA
1 shared publication - Gertjan Johannes Laurentius Kaspers
Emma Children's Hospital Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
1 shared publication Gladys R J Zandwijken
Dutch Growth Research Foundation, Rotterdam, Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 September 2019
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 11 (3) , 293-300
Intrauterine Twin Discordancy and Partial Postnatal Catch-up Growth in a Girl with a Pathogenic IGF1R Mutation
Objective: Insulin like growth factors-I (IGF-1) is essential for normal in utero and postnatal human growth. It mediates its effects through the IGF-1 receptor (IGFIR), a widely expressed cell surface tyrosine kinase receptor. The aim of the study was to analyze pre- and post-natal growth, clinical features and laboratory findings in a small for gestational age (SGA) girl in whom discordant postnatal growth persisted and her appropriate for gestational age (AGA) brother. Methods: A girl born with a low weight and length [-2.3 and -2.4 standard deviation (SD) score (SDS), respectively] but borderline low head circumference (-1.6 SD) presented with a height of -1.7 SDS, in contrast to a normal height twin brother (0.0 SDS). IGF-I resistance was suspected because of elevated serum IGF- I levels. Results: Sequencing revealed the presence of a previously described pathogenic heterozygous mutation (p.Glu1050Lys) in the SGA girl which was not present in the parents nor in the AGA twin brother. Conclusion: The pathogenic IGFIR mutation in this girl led to intrauterine growth retardation followed by partial postnatal catch-up growth. Height in mid-childhood was in the lower half of the reference range, but still 1.7 SD shorter than her twin brother.
- 1 September 2019
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 11 (3) , 293-300
Open AccessIntrauterine Twin Discordancy and Partial Postnatal Catch-up Growth in a Girl with a Pathogenic IGF1R Mutation
Objective: Insulin like growth factors-I (IGF-1) is essential for normal in utero and postnatal human growth. It mediates its effects through the IGF-1 receptor (IGFIR), a widely expressed cell surface tyrosine kinase receptor. The aim of the study was to analyze pre- and post-natal growth, clinical features and laboratory findings in a small for gestational age (SGA) girl in whom discordant postnatal growth persisted and her appropriate for gestational age (AGA) brother. Methods: A girl born with a low weight and length [-2.3 and -2.4 standard deviation (SD) score (SDS), respectively] but borderline low head circumference (-1.6 SD) presented with a height of -1.7 SDS, in contrast to a normal height twin brother (0.0 SDS). IGF-I resistance was suspected because of elevated serum IGF- I levels. Results: Sequencing revealed the presence of a previously described pathogenic heterozygous mutation (p.Glu1050Lys) in the SGA girl which was not present in the parents nor in the AGA twin brother. Conclusion: The pathogenic IGFIR mutation in this girl led to intrauterine growth retardation followed by partial postnatal catch-up growth. Height in mid-childhood was in the lower half of the reference range, but still 1.7 SD shorter than her twin brother.
- 8 March 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (8) , 3157-3171
Phenotypic Features and Response to GH Treatment of Patients With a Molecular Defect of the IGF-1 Receptor
Context The phenotype and response to growth hormone (GH) treatment of children with a IGF1R defect is insufficiently known. Objective To develop a clinical score for selecting short children for genetic testing and evaluate the efficacy of treatment. Design, setting Case series with an IGF1R defect identified in a university genetic laboratory. Patients, interventions Of all patients with sufficient clinical data, 18 had (likely) pathogenic mutations (group 1) and 7 had 15q deletions including IGF1R (group 2), 19 patients were treated with GH. Main outcome measures Phenotype and response to GH treatment. Results In groups 1 and 2, mean (range) birth weight, length and head circumference (HC) SDS were -2.1 (-3.7 to -0.4), -2.7 (-5.0 to -1.0) and -1.6 (-3.0 to 0.0), respectively. At presentation, height, HC and serum IGF-1 SDS were -3.0 (-5.5 to -1.7), -2.5 (-4.2 to -0.5), and +1.2 SDS (-1.3 to 3.2), respectively. Feeding problems were reported in 15/19. A clinical score with 76 % sensitivity is proposed. After 3 years of GH treatment [1.1(0.2) mg/m2.day] height gain in groups 1 (n=12) and 2 (n=7) was 0.9 SDS and 1.3 SDS (at a mean IGF-1 of 3.5 SDS), less than reported for SGA (1.8 SDS). Conclusion A clinical score encompassing birth weight and/or length, short stature, microcephaly and IGF-1 is useful for selecting patients for IGF1R analysis. Feeding problems are common and the growth response to GH treatment is moderate.
- 8 March 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (8) , 3157-3171
Phenotypic Features and Response to GH Treatment of Patients With a Molecular Defect of the IGF-1 Receptor
Context The phenotype and response to growth hormone (GH) treatment of children with a IGF1R defect is insufficiently known. Objective To develop a clinical score for selecting short children for genetic testing and evaluate the efficacy of treatment. Design, setting Case series with an IGF1R defect identified in a university genetic laboratory. Patients, interventions Of all patients with sufficient clinical data, 18 had (likely) pathogenic mutations (group 1) and 7 had 15q deletions including IGF1R (group 2), 19 patients were treated with GH. Main outcome measures Phenotype and response to GH treatment. Results In groups 1 and 2, mean (range) birth weight, length and head circumference (HC) SDS were -2.1 (-3.7 to -0.4), -2.7 (-5.0 to -1.0) and -1.6 (-3.0 to 0.0), respectively. At presentation, height, HC and serum IGF-1 SDS were -3.0 (-5.5 to -1.7), -2.5 (-4.2 to -0.5), and +1.2 SDS (-1.3 to 3.2), respectively. Feeding problems were reported in 15/19. A clinical score with 76 % sensitivity is proposed. After 3 years of GH treatment [1.1(0.2) mg/m2.day] height gain in groups 1 (n=12) and 2 (n=7) was 0.9 SDS and 1.3 SDS (at a mean IGF-1 of 3.5 SDS), less than reported for SGA (1.8 SDS). Conclusion A clinical score encompassing birth weight and/or length, short stature, microcephaly and IGF-1 is useful for selecting patients for IGF1R analysis. Feeding problems are common and the growth response to GH treatment is moderate.
- 1 June 2011
- Published by Springer Nature in Tijdschrift voor kindergeneeskunde
- Vol. 79 (3) , 87-91
Bijnierschorsinsufficiëntie door glucocorticoïdgebruik in de oncologie op de kinderleeftijd
- 1 June 2011
- Published by Springer Nature in Tijdschrift voor kindergeneeskunde
- Vol. 79 (3) , 87-91
Bijnierschorsinsufficiëntie door glucocorticoïdgebruik in de oncologie op de kinderleeftijd
- 1 January 2009
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 22 (8) , 751-758
A Case of Premature Thelarche With No Central Cause or Genetic Variants Within the Estrogen Receptor Signaling Pathway
Premature thelarche is defined as breast development before 8 years of age. This is most often caused by central hormone disregulation and is accompanied by concurrent bone maturation. However, we present a case of premature thelarche with concurrent bone maturation without central hormone disregulation. Genes within the estrogen signaling pathway were examined for genetic changes which might be responsible for the clinical phenotype. A girl presented with breast development from 18 months of age with undetectable serum estrogens, prepubertal serum gonadotropins, advanced growth and skeletal maturation, but no increase of uterine size, thus presenting a premature thelarche variant. Serum estrogens remained below detectable limits until she entered into an unremarkable puberty at 12.1 years of age. No abnormalities or SNPs were found in the genes tested. We describe a case of premature thelarche which cannot be attributed to a central cause of abnormal hormone levels or to alterations in genes suspected for this phenotype. We conclude that other yet to be identified factors are involved in this unique case of premature thelarche.
- 1 January 2009
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 22 (8) , 751-758
A Case of Premature Thelarche With No Central Cause or Genetic Variants Within the Estrogen Receptor Signaling Pathway
Premature thelarche is defined as breast development before 8 years of age. This is most often caused by central hormone disregulation and is accompanied by concurrent bone maturation. However, we present a case of premature thelarche with concurrent bone maturation without central hormone disregulation. Genes within the estrogen signaling pathway were examined for genetic changes which might be responsible for the clinical phenotype. A girl presented with breast development from 18 months of age with undetectable serum estrogens, prepubertal serum gonadotropins, advanced growth and skeletal maturation, but no increase of uterine size, thus presenting a premature thelarche variant. Serum estrogens remained below detectable limits until she entered into an unremarkable puberty at 12.1 years of age. No abnormalities or SNPs were found in the genes tested. We describe a case of premature thelarche which cannot be attributed to a central cause of abnormal hormone levels or to alterations in genes suspected for this phenotype. We conclude that other yet to be identified factors are involved in this unique case of premature thelarche.